☆ 4.2 Article

Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Thomas Martin et al.

Summary: PURPOSECARTITUDE-1, a phase Ib/II study, evaluated the safety and efficacy of Ciltacabtagene Autoleucel in heavily treated patients with relapsed/refractory multiple myeloma. The study showed early, deep, and durable responses at 12 months, with updated results at 2 years. Patients received a single infusion of Ciltacabtagene Autoleucel and responses were assessed.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodriguez-Otero et al.

Summary: In this international phase 3 trial, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, was found to significantly prolong progression-free survival and improve response compared to standard regimens in patients with relapsed and refractory multiple myeloma. The toxicity of ide-cel was consistent with previous reports.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Hematology

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi et al.

Summary: Lisocabtagene maraleucel, an autologous CD19-directed CAR T-cell therapy, shows promising safety and efficacy in patients with relapsed/refractory CLL/SLL, providing a potential new treatment option for these patients who develop resistance to current therapies.

BLOOD (2022)

Add to Collection

Article Oncology

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson et al.

Summary: This study assessed the use of axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma and found that it showed high rates of durable responses and had a manageable safety profile.

LANCET ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Hale Fowler et al.

Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia

Franco Locatelli et al.

Summary: The study demonstrates that betibeglogene autotemcel therapy can achieve transfusion independence in patients with transfusion-dependent beta-thalassemia, with good safety profile and stable results, suitable for most patients with non-beta(0)/beta(0) genotype.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

F. L. Locke et al.

Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar et al.

LANCET (2022)

Add to Collection

Article Oncology

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison Sehgal et al.

Summary: The study evaluated the efficacy and safety of lisocabtagene maraleucel as second-line treatment for patients with large B-cell lymphoma, showing potential therapeutic effects with some treatment-related adverse events.

LANCET ONCOLOGY (2022)

Add to Collection

Meeting Abstract Hematology

New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Kris Michael Mahadeo et al.

BLOOD (2022)

Add to Collection

Article Hematology

Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Miguel-Angel Perales et al.

Summary: Three CD19-directed CAR T cell therapies have been approved for second-line treatment of relapsed/refractory aggressive diffuse large B cell lymphoma. Different clinical trials have shown significant improvement with CD19 CAR T cells in second-line therapy, but there are still differences in treatment outcomes.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Add to Collection

Article Hematology

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

Binod Dhakal et al.

Summary: Therapeutic options in multiple myeloma have changed dramatically in the past decade. A panel of experts formulated clinical practice recommendations for the role, timing, and sequencing of autologous and allogeneic hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell therapy. The panel endorsed the use of auto-HCT consolidation for newly diagnosed patients and recommended its use in the first relapse for patients not undergoing upfront auto-HCT.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Add to Collection

Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Amod A. Sarnaik et al.

Summary: This study showed that Lifileucel is effective in treating advanced melanoma, especially in patients who are refractory to PD-1 or PD-L1 therapy. The product provides durable responses and addresses a major unmet need in patients with limited treatment options after approved therapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

Engineering the next generation of CAR-NK immunotherapies

Alexander Biederstaedt et al.

Summary: Cellular immunotherapy, particularly CAR-NK therapy, has shown promising efficacy in treating hematologic malignancies. Research is focused on enhancing CAR-NK cell potency and translating successful strategies to solid tumor treatments.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Immune effector cell therapies in oncology: A systematic analysis and forecast from ClinicalTrials.gov.

Jose Vicente Forero-Forero et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Bijal D. Shah et al.

Summary: KTE-X19 demonstrated a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Median overall survival was not reached in responding patients, and the therapy showed a manageable safety profile. These findings suggest that KTE-X19 has the potential to provide long-term clinical benefit to these patients.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesus G. Berdeja et al.

Summary: The study aimed to evaluate the safety and clinical activity of cilta-cel in patients with relapsed or refractory multiple myeloma, and the results showed that cilta-cel treatment achieved good efficacy and safety with short treatment duration, deep response, and long duration of response.

LANCET (2021)

Add to Collection

Article Oncology

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster et al.

Summary: The JULIET trial evaluated the long-term treatment outcomes and safety of tisagenlecleucel in adult patients, showing durable activity and manageable safety profiles in patients with relapsed or refractory aggressive B-cell lymphomas. Tisagenlecleucel compared favorably with conventional therapeutic approaches for patients with large B-cell lymphomas that are refractory to chemoimmunotherapy or relapsing after second-line therapies.

LANCET ONCOLOGY (2021)

Add to Collection

Article Hematology

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Pashna N. Munshi et al.

Summary: Experts convened to formulate consensus recommendations for the role, timing, and sequencing of auto-HCT, allo-HCT, and CAR T cell therapy for MCL patients, generating 17 consensus statements. The study highlights the importance of treatment choices at different stages.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Review Immunology

CAR-NK cells: the next wave of cellular therapy for cancer

May Daher et al.

Summary: CAR-NK cells, derived from non-αβ T-cell immune effector cells, are gaining interest as a promising alternative to CAR-T therapy in cancer treatment. Studies have shown the potential of CAR-NK cells in enhancing antitumor activity and novel strategies are being investigated to further improve their efficacy.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)

Add to Collection

Article Hematology

Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy

Abraham S. Kanate et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

Add to Collection

Article Medicine, General & Internal

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Carlos A. Ramos et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson et al.

LANCET (2020)

Add to Collection

Review Oncology

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma

Robert J. Cronk et al.

CANCERS (2020)

Add to Collection

Article Medicine, General & Internal

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Noopur Raje et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Hematology

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Tania Jain et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Article Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Frederick L. Locke et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article

Clinical Utilization of Chimeric Antigen Receptors T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation

Ankit J. Kansagra et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Hematology

Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation

Navneet S. Majhail et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)

Add to Collection

Article Hematology

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

Waleed Haso et al.

BLOOD (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.